Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Catherine C SmithAaron D VinyEvan MassiCyriac KandothNicholas D SocciFranck RapaportMatthieu NajmJuan Santiago Medina-MartinezElli PapaemmanuilTheodore C TarverHenry H HsuMai H LeBrian WestGideon BollagBarry S TaylorRoss L LevineNeil P ShahPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Mutations in CCND3, a gene not commonly mutated in AML, are a novel cause of clinical primary resistance to FLT3 inhibitors in AML and may have sensitivity to CDK4/6 inhibition.